NEWRON (EGFF)

Promoteur – Intermédiaire Financier

NEWRON PHARMACEUTICALS SPA

Lieu

• Italie

Description

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system. The company is operational and already has one drug on the market (Xadago). The investment programme consists of the discovery, pre-clinical and clinical development of a portfolio of assets, addressing different therapeutic areas focusing on underserved neurological conditions. The candidates are at various developmental stages.

Objectifs

This project will help provide novel therapies for patients with underserved neurological conditions.

Secteur(s)

• Services - Activités spécialisées, scientifiques et techniques

Montant BEI envisagé (montant approximatif)

EUR 40 million

Coût total (montant approximatif)

EUR 92 million

Aspects environnementaux

The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

Passation des marchés

The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

Statut

Signé - 29/10/2018